Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266243 | 0.81 | CYP2A6 (0.44) | ERN1ALDH1A1SMN1; SMN2CYP2A6MAPT | |
| SCHEMBL22607120 | 0.79 | ACHE (0.38) | ACHEERN1CNR2SMN1; SMN2GPR55 | |
| SCHEMBL10731147 | 0.74 | CYP2A6 (0.37) | CYP2A6NPC1 | |
| SCHEMBL787838 | 0.73 | NQO2 (0.40) | ALDH1A1SMN1; SMN2CYP3A4NPC1MAPT | |
| SCHEMBL15424071 | 0.71 | ACHE (0.62) | ACHEERN1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22132796 | 0.69 | ACHE (0.43) | ACHEERN1CNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3483738 | 0.67 | TAAR1 (0.38) | ALDH1A1CYP2A6CYP3A4 | |
| SCHEMBL3483704 | 0.67 | CYP2A6 (0.37) | ALDH1A1CYP2A6CYP3A4 | |
| SCHEMBL22186841 | 0.67 | MRGPRX1 (0.31) | — | |
| SCHEMBL18740662 | 0.66 | ACHE (0.39) | ACHEERN1CNR2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670513-B1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20200339606-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236094-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | ACHE 4885/4885ERN1 3460/4885CNR2 3264/4885 |
| US-20200339606-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BPGM, BRCA1, BRAP | ACHE 4734/4885ERN1 3226/4885CNR2 4136/4885 |
| US-20200207773-A1 | FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF | FGFR1, FGFR2, FGFR3 | ACHE 4883/4885ERN1 3106/4885CNR2 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.